OptiCell Solutions AB announce the collaboration with CTC, Clinical Trial Consultants AB

PRESS RELEASE
OptiCell Solutions AB announce the collaboration with CTC, Clinical Trial Consultants AB
Huddinge, Sweden 25-JUN-2025

Exciting News from OptiCell Solutions
We are happy to announce the next step in our journey toward advancing patient care by officially partnering with CTC.

We are happy to announce the next step in our journey toward advancing patient care through our official partnership between OptiCell Solutions and CTC. Together, we are addressing a key challenge in advanced therapy research: securing timely access to high-quality cell collection and apheresis. With established bases in Huddinge and Uppsala, and a shared ambition to scale this capacity to additional cities across Sweden, we are strengthening the national infrastructure needed to support cutting-edge cell and gene therapy development.

By offering specialized services in this critical area, we aim to eliminate bottlenecks and ensure timely, efficient cell collection for research. This presents an exciting new opportunity for biotech and pharmaceutical companies, CROs, Medtech’s and healthcare providers to accelerate their programs.

“Together, we want to be involved in the development of ATMPs (Advanced Therapy Medicinal Products) by offering high-quality cell collections for research – the fastest growing segment in precision medicine – and focus on collecting target cells with our unique expertise in research ethics as well in apheresis technology to give researchers an excellent starting point in the development of new treatments for cancer diseases and autotherapies,” says Jarmo Henriksson, CEO of OptiCell Solutions.

“The collaboration with OptiCell is a direct response to the increasing demand for apheresis from our clients in cell and gene therapy. By combining our expertise, we can now offer a more complete solution — from preclinical development through to clinical studies — tailored to the needs of each client”, says Anders Millerhovf, CEO at CTC.
Stay tuned for more updates on how this partner and future partnership will benefit the future of advanced therapies.

— END PRESS RELEASE—

PRESS RELEASE 25-JUN-2025_OptiCell

For more information, please contact
General Manager, Jarmo Henriksson, +46 (0) 73 699 48 37, jarmo.henriksson@opticellsolutions.com
Chairman of the board, Peter Rybäck, +46 (0) 73 849 07 96, peter.ryback@opticellsolutions.com

About OptiCell Solutions
Founded in 2024, OptiCell Solutions AB specializing in the field of apheresis collection for Cell and Gene Therapy (CGT). By using our advanced apheresis technology, we can collect large quantities of specific donor cells, significantly advancing applications within in the CGT. Furthermore, our extensive experience and know-how in apheresis enable us to offer specialized therapeutic apheresis services to the healthcare sector.
Located near the Karolinska University Hospital in Huddinge we aim to bridge the gap in resources by offering innovative solutions that enhance the availability of essential cells for cutting-edge research and life-saving therapies. With our deep expertise in apheresis technology and a strong commitment to ethical research practices, we are dedicated to improving patient outcomes and supporting the development of next-generation therapies for cancer care, autoimmune diseases, and other severe medical conditions.
At OptiCell Solutions, we strive to be at the forefront of medical innovation, providing the tools and services necessary to accelerate the transition to more effective and patient-centred care. For more information visit our website, www.opticellsolutions.com and follow us at LinkedIn.

About CTC Clinical Trial Consultants AB
Founded 2011, CTC is a full-service CRO with a focus on early phase clinical trials. Our mission is to facilitate clinical and translational research by providing our customers with cost-effective advice, and conduct and reporting of clinical trials. CTC together is capable of assuming full responsibility for your clinical development program, starting from the initial translation of preclinical data into the human setting and extending through Phase II. Our approach emphasizes transparent collaboration and a cohesive partnership with our clients. We perform in-house clinical conduct at our first-in-human (FIH) and Phase I-IV clinical research units in Uppsala, Stockholm, Linköping and Gothenburg. Our clinics work in close collaboration with our Project Management, Clinical Monitoring, Medical Writing, Biometrics, Pharmacovigilance and DMPK & Clinical Pharmacology departments to provide a true full-service option to our customers.
For more information visit our website, www.ctc-ab.se